Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Vaccine Development & Manufacturing

Virxsys Corporation

Attachments

*Architects: Biotechnology_DNA, RNA, RNAi, siRNA & mRNA
*Architects: Vaccine Development & Manufacturing
*Industry: Gaithersburg, Maryland
*Industry: Maryland (Medical & Health Information Technology, Biomedical, Biopharmaceutical & Biotechnology Sectors)
Venture Capital: Series F

Founded 1989
Gaithersburg, Maryland
SMaRT™ is VIRxSYS’s proprietary spliceosome-mediated RNA trans-splicing technology for reprogramming and repair of gene expression at the RNA level.
The Company has exclusively licensed its patented, proprietary lentiviral technology platform from The Johns Hopkins University (JHU) in Baltimore, Maryland
The Company obtained its SMaRT™ technology from Intronn Inc
The company was founded in 1998 and has raised a total of $87 million (2006)
This technology has broad therapeutic applications, encompassing siRNA, miRNA and Antigomirs.
VIRxSYS Awarded Maryland Stem Cell Grant (2010)
VIRXSYS COMPLETES $30 MILLION FINANCING (2005)
VIRxSYS Corp. Raises $33.8M (2011)
VIRxSYS is a private biotechnology company that focuses on the development of a novel lentiviral gene delivery platform technology for the treatment of serious diseases.
VIRxSYS President and CEO Riku Rautsola, Ph.D.
VIRXSYS RAISES $20 MILLION IN FINANCING (2006)
Virysys Completes CRADA w/NHLBI (2007)